Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapansutrile in well-controlled Schnitzler's syndrome after anakinra withdrawal
NL-OMON46617Phase 2Active, not recruiting
- Sponsor
- Olatec Therapeutics LLC
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dapansutrile in Schnitzler syndrome, sponsored by Olatec Therapeutics LLC. Primary endpoint: Proportion of subjects with Grade 0 or 1 Schnitzler syndrome symptoms at Day 14. Started May 2018; status: active, not recruiting.
02
Drugs
dapansutrile
03
Conditions
Schnitzler syndrome
Beyond the preview
Go deeper on NL-OMON46617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46617.